Radiopharm RAD101 meets Phase 2b endpoint for brain metastases

July 22, 2026 7:00 AM

Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) reported that its RAD101 imaging agent met the primary endpoint of a Phase 2b ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found